Retrospective analysis of patients in a multi-center study assessing change in management strategy following Envisia and cryobiopsy and the association between Envisia UIP classification and disease progression. Results showed combining Envisia with Cryobiopsy demonstrated meaningful impact on therapeutic strategy for ILD patients. Envisia positive patients who were not prescribed antifibrotics were twice as likely to progress compared to Envisia negative patients.

In this Bronchoscopy Blitz segment, Interventional Pulmonologist, Dr. Fayez Kheir shares the latest data on the role of Envisia in the diagnosis and prognosis of ILD patients including application of the test in combination with cryobiopsy.

Review findings from a retrospective analysis of 135 patients from the BRAVE trial examined the impact of an Envisia Genomic Classifier result on FVC progression at 12 months. The study found that Envisia may serve as a biomarker of progression across a range of ILD patients and could prompt earlier treatment intervention to slow progression.

Listen to ILD experts provide an overview of their MDD and how the Envisia Genomic Classifier can be integrated into the ILD diagnostic algorithm. This ATS industry innovations webinar recording also includes a review and discussion of 3 real world cases in which the genomic classifier test impacted decision making.